-
Liraglutide: Promise of the Incretin Class; Low-glycemic Index Diet in Type 2 Diabetics; Glucose Control and Macrovascular Disease; Risks Associated with the Morning BP Surge; Simplifying Dosing for Actinic Keratoses; Aerobic and Resistance Training Effects in PAD;
-
The stars were aligned when four papers appeared in two obstetrical journals within a month of each other dealing with the optimal time in gestation to deliver.
-
The above study involved a detailed analysis of data obtained in the observational arm of the Women's Health Initiative. As a rationale, the authors note that obesity is a well-established risk factor for breast cancer.
-
Cromer et al performed a 24-month observational, prospective cohort study of adolescents in the Midwest using depot medroxyprogesterone acetate (DMPA), oral contraceptives (OCs), or nothing. DEXA scans were performed at baseline and 6-month intervals.
-
A 3-year randomized, double-blind clinical trial in 206 sites throughout the world compared bazedoxifene (20 mg or 40 mg) and raloxifene (60 mg) with placebo.
-
A randomized, double-blind, placebo-controlled trial comparing Ginkgo biloba with placebo for the prevention of dementia enrolled 3069 elderly individuals (older than age 75) in 5 academic centers in the United States.
-
In this issue: Drug combinations for hypertension; tenecteplase for out-of-hospital cardiac arrest; CAM most commonly used for back, neck, and arthritis pain; FDA Actions.
-
-
With the inauguration of President Barack Obama and with expanded Democratic majorities in both chambers of Congress, reproductive health supporters in the administration, in Congress, and outside the government are entering the new year with renewed optimism.
-
When it comes to current methods of delivery of hormonal contraception, women now can choose among pill, patch, ring, implant, and intrauterine forms of birth control.
